Noninvasive assessment of cancer response to therapy

Han, Zhibin; Fu, Allie; Wang, Hailun; Díaz, Roberto; Geng, Li; Onishko, Halina; Hallahan, Dennis E.

doi:10.1038/nm1691

Cited by 61 publications

(75 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using phage display, Han et al (39) have identified peptides that bind specifically to tumors that respond to a combination of antiangiogenic therapy and radiotherapy. Radiolabeled analogs of these peptides could be used for PET-based monitoring of early treatment responses (39). In addition to PET, other noninvasive imaging modalities such as MRI (40) and CT (41) could also prove useful.…”

Section: Additional Mechanisms Of Dfdc Resistance and Potential Limitmentioning

confidence: 99%

Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography

Laing

Walter²,

Campbell³

et al. 2009

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Gemcitabine (2 ,2 -difluorodeoxycytidine, dFdC) and cytosine arabinoside (cytarabine, ara-C) represent a class of nucleoside analogs used in cancer chemotherapy. Administered as prodrugs, dFdC and ara-C are transported across cell membranes and are converted to cytotoxic derivatives through consecutive phosphorylation steps catalyzed by endogenous nucleoside kinases. Deoxycytidine kinase (DCK) controls the rate-limiting step in the activation cascade of dFdC and ara-C. DCK activity varies significantly among individuals and across different tumor types and is a critical determinant of tumor responses to these prodrugs. Current assays to measure DCK expression and activity require biopsy samples and are prone to sampling errors. Noninvasive methods that can detect DCK activity in tumor lesions throughout the body could circumvent these limitations. Here, we demonstrate an approach to detecting DCK activity in vivo by using positron emission tomography (PET) and 18

show abstract

Section: Additional Mechanisms Of Dfdc Resistance and Potential Limitmentioning

confidence: 99%

Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography

Laing

Walter²,

Campbell³

et al. 2009

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…Significant changes in tumor volume usually happen only after a patient is treated for a prolonged length of time, and certain disease sites are not readily accessible to repeated biopsies. To address these issues, a remarkable study applied in vivo homing with a T7 phage peptide library to identify clones that only recognized tumors that were responsive to therapy (Han et al 2008). In these studies, lung carcinoma or glioblastoma xenograft models were treated with vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors in combination with radiation prior to in vivo homing selections.…”

Section: Molecular Imaging Agents Obtained Through Phage Selections Imentioning

confidence: 99%

“…Shown are NIR images obtained 48 hours after peptide injection. Reprinted by permission from Macmillan Publishers Ltd (Han et al 2008).…”

Section: Molecular Imaging Agents Obtained Through Phage Selections Imentioning

confidence: 99%

Phage display and molecular imaging: expanding fields of vision in living subjects

Cochran

2010

Biotechnology and Genetic Engineering Reviews

View full text Add to dashboard Cite

In vivo molecular imaging enables non-invasive visualization of biological processes within living subjects, and holds great promise for diagnosis and monitoring of disease. The ability to create new agents that bind to molecular targets and deliver imaging probes to desired locations in the body is critically important to further advance this field. To address this need, phage display, an established technology for the discovery and development of novel binding agents, is increasingly becoming a key component of many molecular imaging research programs. This review discusses the expanding role played by phage display in the field of molecular imaging with a focus on in vivo applications. Furthermore, new methodological advances in phage display that can be directly applied to the discovery and development of molecular imaging agents are described. Various phage library selection strategies are summarized and compared, including selections against purified target, intact cells, and ex vivo tissue, plus in vivo homing strategies. An outline of the process for converting polypeptides obtained from phage display library selections into successful in vivo imaging agents is provided, including strategies to optimize in vivo performance. Additionally, the use To whom correspondence may be addressed (cochran1@stanford.edu) Abbreviations: scFv, single chain variable fragment; Fab, fragment antigen binding; ELISA, Enzyme-Linked Immunosorbent Assay; NEB, New England Biolabs; PET, positron emission tomography; SPECT, single photon emission computed tomography; NIR, near infrared; PEG, polyethylene glycol; SPARC, secreted protein acidic and rich in cysteine; VCAM-1, vascular cell adhesion molecule; MRI, magnetic resonance imaging; DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; IC 50 , half maximal inhibitory concentration; CT, computed tomography; K D , equilibrium dissociation constant; EGFR, epidermal growth factor receptor; EGFR-ECD, EGFR extracellular domain; Aβ 42 , amyloid-beta; MMP, matrix metalloprotease; uPAR, urokinase-type plasminogen activator receptor; VEGF, vascular endothelial growth factor; IL-11, Interleukin-11; IL-11αR, Interleukin-11 α-receptor. 58F.V. CoChran and J.r. CoChran of phage particles as imaging agents is also described. In the latter part of the review, a survey of phage-derived in vivo imaging agents is presented, and important recent examples are highlighted. Other imaging applications are also discussed, such as the development of peptide tags for site-specific protein labeling and the use of phage as delivery agents for reporter genes. The review concludes with a discussion of how phage display technology will continue to impact both basic science and clinical applications in the field of molecular imaging.

show abstract

“…Radiation as part of cancer therapy is known to elicit expression pattern changes in the tumor microvasculature (55). Phage display techniques have been used to probe irradiated tumors and identify peptides that bind to newly expressed, tumor-specific neoantigens for diagnostic purposes (56) or to target nanoparticle therapeutics (57,58). When peptide-targeted doxorubicin liposomes are delivered, irradiated tumors accumulate more drug than nonirradiated tumors after 3 d in an s.c. model of lung cancer in mice (57).…”

Section: Environment-primed Nanosystemsmentioning

confidence: 99%

Smart nanosystems: Bio-inspired technologies that interact with the host environment

Kwon

Bhatia

2015

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Nanoparticle technologies intended for human administration must be designed to interact with, and ideally leverage, a living host environment. Here, we describe smart nanosystems classified in two categories: (i) those that sense the host environment and respond and (ii) those that first prime the host environment to interact with engineered nanoparticles. Smart nanosystems have the potential to produce personalized diagnostic and therapeutic schema by using the local environment to drive material behavior and ultimately improve human health.nanosystems | smart nanomaterials | environment-responsive | host priming | cancer nanotechnology

show abstract

Noninvasive assessment of cancer response to therapy

Cited by 61 publications

References 19 publications

Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography

Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography

Phage display and molecular imaging: expanding fields of vision in living subjects

Smart nanosystems: Bio-inspired technologies that interact with the host environment

Contact Info

Product

Resources

About